MyMedR

Fulltext A cohort study of risk factors and clinical outcome predictors for patients presenting with unstable angina and non ST segment elevation myorardial infraction undergoing coronary intervention

Chong E, Shen L, Tan HC, Poh KK

Med J Malaysia, 2011 Aug;66(3):249-52.

PMID: 22111450

Thrombolysis in Myocardial Infarction (TIMI) score has been used to predict outcomes in patients presenting with unstable angina (UA) and non-ST elevation myocardial infarction (NSTEMI). Our study assessed other clinical predictors for patients with UA/NSTEMI undergoing early percutaneous coronary intervention (PCI).

Matched MeSH terms: Angioplasty, Balloon, Coronary*

Fulltext Acute myocardial infarction in young Asian women: a comparative study on Chinese, Malay and Indian ethnic groups

Xie CB, Chan MY, Teo SG, Low AF, Tan HC, Lee CH

Singapore Med J, 2011 Nov;52(11):835-9.

PMID: 22173254

There is a paucity of data on acute myocardial infarction (AMI) in young Asian women and of comparative data among various ethnic groups with respect to risk factor profile and clinical outcomes. We present a comprehensive overview of the clinical characteristics of young Asian women with AMI and a comparative analysis among Chinese, Malay and Indian women in a multi-ethnic Asian country.

Matched MeSH terms: Angioplasty, Balloon, Coronary/methods

Fulltext Are there gender differences in coronary artery disease? The Malaysian National Cardiovascular Disease Database - Percutaneous Coronary Intervention (NCVD-PCI) Registry

Lee CY, Hairi NN, Wan Ahmad WA, Ismail O, Liew HB, Zambahari R, et al.

PLoS One, 2013;8(8):e72382.

PMID: 24015238 DOI: 10.1371/journal.pone.0072382

To assess whether gender differences exist in the clinical presentation, angiographic severity, management and outcomes in patients with coronary artery disease (CAD).

Matched MeSH terms: Angioplasty, Balloon, Coronary

Back to the future: drug eluting balloon in bifurcation intervention

Choo GH, Le D, Nguyen K, Phan H, Nguyen Q, Nguyen J

Chin Med J (Engl), 2012 Oct;125(19):3565-8.

PMID: 23044325

Matched MeSH terms: Angioplasty, Balloon, Coronary

Bailout left main bioresorbable vascular scaffolding for the treatment of iatrogenic coronary dissection induced by guiding catheter and sticky ABSORB bioresorbable vascular scaffold balloon

Yew KL

Int J Cardiol, 2015;187:527-9.

PMID: 25846666 DOI: 10.1016/j.ijcard.2015.03.432

Matched MeSH terms: Angioplasty, Balloon, Coronary/adverse effects; Angioplasty, Balloon, Coronary/methods*

Fulltext Cardiovascular event in chronic myeloid leukaemia treated with tyrosine kinase inhibitor: a case report

Boo YL, Liam CCK, Lim SY, Look ML

Hong Kong Med J, 2019 Feb;25(1):74-5.

PMID: 30713145 DOI: 10.12809/hkmj176972

Matched MeSH terms: Angioplasty, Balloon, Coronary

Clinical experience in coronary stenting with the Vivant Z Stent

Chee KH, Siaw FS, Chan CG, Chong WP, Imran ZA, Haizal HK, et al.

Int J Clin Pract, 2005 Jun;59(6):628-31.

PMID: 15924588

This single centre study was designed to demonstrate feasibility, safety and efficacy of the Vivant Z stent (PFM AG, Cologne, Germany). Patients with de novo lesion were recruited. Coronary angioplasty was performed with either direct stenting or after balloon predilatation. Repeated angiogram was performed 6 months later or earlier if clinically indicated. Between January to June 2003, a total of 50 patients were recruited (mean age 55.8 +/- 9 years). A total of 52 lesions were stented successfully. Mean reference diameter was 2.77 mm (+/-0.59 SD, range 2.05-4.39 mm) with mean target lesion stenosis of 65.5% (+/-11.6 SD, range 50.1-93.3%). Forty-six lesions (88.5%) were American College of Cardiologist/American Heart Association class B/C types. Direct stenting was performed in 18 (34.6%) lesions. Mean stent diameter was 3.18 mm (+/-0.41 SD, range 2.5-4 mm), and mean stent length was 14.86 mm (+/-2.72 SD, range 9-18 mm). The procedure was complicated in only one case which involved the loss of side branch with no clinical sequelae. All treated lesions achieved Thrombolysis In Myocardial Infarction 3 flow. Mean residual diameter stenosis was 12.2% (+/-7.55 SD, range 0-22.6%) with acute gain of 1.72 mm (+/-0.50 SD, range 0.5-2.8). At 6 months, there was no major adverse cardiovascular event. Repeated angiography after 6 months showed a restenosis rate of 17% (defined as >50% diameter restenosis). Mean late loss was 0.96 mm (+/-0.48 SD) with loss index of 0.61 (+/-0.38 SD). The restenosis rate of those lesions less than 3.0 mm in diameter was 22.2% compared with 6.25% in those lesions more than 3.0 mm in diameter. The Vivant Z stent was shown to be safe and efficacious with low restenosis rate in de novo coronary artery lesion.

Matched MeSH terms: Angioplasty, Balloon, Coronary*

Computed tomography scan for cardiac interventions

Sim KH, Ong TK, Chin SP, Wong M

Indian Heart J, 2007 Mar-Apr;59(2 Suppl B):B25-32.

PMID: 19153433

Matched MeSH terms: Angioplasty, Balloon, Coronary*

Fulltext Coronary stents in the management of coronary artery disease review of first 100 stents

Ng SC, Sawatt C, Foo LK, Hitam O, Khor PG, Lee YK

Med J Malaysia, 1996 Mar;51(1):75-9.

PMID: 10967983

This is a review of the first 100 coronary stents implanted for the indications of PTCA restenosis, acute or threatened closure and De Novo lesions. The success rates were high and complications rates were low. Subacute stent thrombosis rates were low and stenting for De Novo lesions in > 3.0 mm arteries provide the best short and long term results. Six months restenosis rate was low. Stent assisted high pressure balloon angioplasty is an important advance.

Matched MeSH terms: Angioplasty, Balloon, Coronary

Dissolution of thrombus formed during direct coronary angioplasty with a single 10 mg intracoronary bolus dose of abciximab

Thuraisingham S, Tan KH

Int J Clin Pract, 1999 Dec;53(8):604-7.

PMID: 10692754

Direct coronary angioplasty with stent implantation is an effective treatment for acute myocardial infarction. The use of adjunctive abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist is expensive. We report on three cases of direct coronary angioplasty complicated by extensive thrombus formation that were successfully treated with attenuated dosing of abciximab via the intracoronary route. All patients presented with acute myocardial infarction complicated by cardiogenic shock or eminent cardiogenic shock. Abciximab was administered after balloon dilatation when extensive thrombus formation was noted and persisted despite repeated inflations. In all three patients a single 10 mg vial of intracoronary abciximab was administered, resulting in complete dissolution of thrombus, allowing successful deployment of stents. Thus, a single 10 mg intracoronary bolus dose of abciximab may be sufficient to achieve high local concentrations of antiplatelet activity. This facilitates thrombus dissolution and allows the safe deployment of a stent to normalise intracoronary rheology.

Matched MeSH terms: Angioplasty, Balloon, Coronary/adverse effects*

Fulltext Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group

Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al.

JACC Cardiovasc Interv, 2020 06 22;13(12):1391-1402.

PMID: 32473887 DOI: 10.1016/j.jcin.2020.02.043

Although drug-eluting stents are still the default interventional treatment of coronary artery disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in certain anatomic conditions. The effect of DCBs is based on the fast and homogenous transfer of antiproliferative drugs into the vessel wall during single balloon inflation by means of a lipophilic matrix without the use of permanent implants. Although their use is established for in-stent restenosis of both bare-metal and drug-eluting stents, recent randomized clinical data demonstrate a good efficacy and safety profile in de novo small-vessel disease and high bleeding risk. In addition, there are other emerging indications (e.g., bifurcation lesions, large-vessel disease, diabetes mellitus, acute coronary syndromes). Because the interaction among the different delivery balloon designs, doses, formulations, and release kinetics of the drugs used is important, there seems to be no "class effect" of DCBs. On the basis of the amount of recently published data, the International DCB Consensus Group provides this update of previous recommendations summarizing the historical background, technical considerations such as choice of device and implantation technique, possible indications, and future perspectives.

Matched MeSH terms: Angioplasty, Balloon, Coronary/adverse effects; Angioplasty, Balloon, Coronary/instrumentation*; Angioplasty, Balloon, Coronary/mortality

Fulltext Early and aggressive ISR with a polymer- and carrier-free drug-coated stent system

Loch A, Bewersdorf JP, Veeriah RS

Indian Heart J, 2017 03 17;69(5):651-654.

PMID: 29054192 DOI: 10.1016/j.ihj.2017.03.002

The LEADERS FREE trial concluded that the polymer free drug-coated BioFreedom™ stent appeared to be both safer and more effective than bare-metal stents (BMS) with an ISR rate comparable to traditional DES without the need for prolonged DAPT. We implanted 45 BioFreedom™ stents in 34 patients over a 4-month period. 4 patients represented early (106-238 days after the implant procedure) with angina symptoms and severe ISR was detected in all patients. The rate of severe and early ISR detected in our patient population of 11.8% is comparable to that of traditional BMS. Further studies are warranted.

Matched MeSH terms: Angioplasty, Balloon, Coronary/methods*

Importance of kissing balloon inflation in bifurcation stenting

Choo GH

J Interv Cardiol, 2009 Apr;22(2):117-20.

PMID: 19379469 DOI: 10.1111/j.1540-8183.2009.00443.x

Percutaneous bifurcation intervention is usually sufficient with a single-stent strategy. When the double-stent strategy is employed, higher restenosis and target lesion revascularization (TLR) rates are observed, especially at the side-branch ostium. The results may be improved, however, with refinement in techniques, for example, final kissing balloon inflation and double kissing balloon inflation.

Matched MeSH terms: Angioplasty, Balloon, Coronary/methods*

In-stent restenosis: the gold standard has changed

Chin K

EuroIntervention, 2011 May;7 Suppl K:K43-6.

PMID: 22027726 DOI: 10.4244/EIJV7SKA7

In-stent restenosis remains an important issue even in the drug-eluting stent (DES) era today. In recent years, drug-eluting balloons (DEB) have emerged as a potential alternative to the treatment of in-stent restenosis. Paclitaxel was identified as the primary drug for DEB because of its rapid uptake and prolonged retention. Non-stent-based local drug delivery using DEB maintains the antiproliferation properties of DES, but without the limitations of DES such as subacute stent thrombosis, stent fractures, prolonged antiplatelet therapy and more importantly, avoiding a "stent-in-a-stent" approach. The first major impact of drug-eluting balloon (DEB) in the management of bare metal instent restenosis was the "PACCOCATH ISR I" randomised trial, comparing the efficacy of drug-eluting balloon versus uncoated balloon. The six months angiographic results showed a binary restenosis of 5% and 4% MACE in the drug-eluting balloon group, compared with 43% binary restenosis and 31% MACE, in the uncoated balloon group (p=0.002 and 0.02). The second major DEB trial is the "PEPCAD II Trial", comparing the efficacy of the SeQuent Please DEB with the Taxus drug-eluting stent in the treatment of bare-metal stent instent restenosis. At 6-month follow-up, in-segment late lumen loss was 0.38 ± 0.61 mm in the DES group versus 0.17 ± 0.42 mm (p=0.03) in the DEB group, resulting in a binary restenosis rate of 12/59 (20%) versus 4/57 (7%; p=0.06). At 12 months, MACE rates were 22% in the Taxus group and 9% in the DEB group (P=0.08). The TLR at 12 months was 15% in the Taxus group and 6% in the DEB group (p=0.15). Based on these two pivotal trials, the European Society of Cardiology Guidelines for Percutaneous Coronary Intervention (2010) recommended that DEB should be considered for the treatment of in-stent restenosis after prior bare-metal stent. This was accorded a class 2 IIa indication, with a level B evidence.

Matched MeSH terms: Angioplasty, Balloon, Coronary/adverse effects; Angioplasty, Balloon, Coronary/instrumentation*

Intracoronary blood sampling with a microcatheter for the diagnosis of giant infective coronary aneurysm: Melioidosis of coronary artery mycotic aneurysm

Yew KL, Choy CN, Kam JY, Kang Z

Int J Cardiol, 2015;187:530-1.

PMID: 25863294 DOI: 10.1016/j.ijcard.2015.04.013

Matched MeSH terms: Angioplasty, Balloon, Coronary

Irreversible delayed complete heart block secondary to jailed first septal perforator following PCI of the left anterior descending coronary artery

Sadiq MA, Azman W, Abidin IZ

J Invasive Cardiol, 2012 Jan;24(1):E13-5.

PMID: 22210591

Permanent complete heart block (CHB) secondary to the loss of first septal perforator after percutaneous coronary intervention (PCI) of the left descending artery (LAD) is an extremely rare complication. We describe a case report where a patient underwent PCI of proximal LAD, complicated by loss of first septal perforator, septal infarction, and bifasicular block, which progressed to symptomatic delayed CHB. One week later, the patient required implantation of a permanent pacemaker following failure to wean off the transvenous temporary pacing maker.

Matched MeSH terms: Angioplasty, Balloon, Coronary*

Fulltext Longitudinal stent compression: a not so new percutaneous coronary angioplasty (PCI) complication

Yew KL, Cham YL

Med J Malaysia, 2012 Feb;67(1):123-4.

PMID: 22582565

Matched MeSH terms: Angioplasty, Balloon, Coronary/adverse effects*

Fulltext Manipal lifestyle modification score to predict major adverse cardiac events in postcoronary angioplasty patients

Devasia T, Shetty PN, Kareem H, Karkala YR, Singh A

Indian Heart J, 2018 Dec;70 Suppl 3(Suppl 3):S353-S358.

PMID: 30595288 DOI: 10.1016/j.ihj.2018.10.411

BACKGROUND: Lifestyle modification (LSM) such as prudent diet, physical activity, avoidance of smoking, and maintaining a healthy weight may considerably decrease the risk for coronary artery disease.

OBJECTIVE: The primary objective of this study was to develop a new LSM scoring system and investigate the correlation between adherence to LSM and incidence of major adverse cardiac events (MACEs) at 12-month follow-up.

METHOD: A total of 1000 consecutive patients who underwent percutaneous transluminal coronary angioplasty (PTCA) were included in this prospective single-center study. Manipal lifestyle modification score (MLSMS) was developed by using five lifestyle-related factors. Adherence to LSM at the baseline and subsequent follow-ups was determined by using MLSMS. The MACE at 1-, 6-, and 12-month follow-up were analyzed.

RESULTS: There was a significant reduction in overall adherence to LSM (p

Matched MeSH terms: Angioplasty, Balloon, Coronary/adverse effects*

Optimization of Stentys Xposition S self-apposing sirolimus eluting stent expansion and apposition with coronary lesion debulking strategy utilizing cutting balloon

Yew KL

Int J Cardiol, 2016 Jan 15;203:1007-8.

PMID: 26630622 DOI: 10.1016/j.ijcard.2015.11.124

Matched MeSH terms: Angioplasty, Balloon, Coronary/methods*

Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus

Ali RM, Degenhardt R, Zambahari R, Tresukosol D, Ahmad WA, Kamar Hb, et al.

EuroIntervention, 2011 May;7 Suppl K:K83-92.

PMID: 22027736 DOI: 10.4244/EIJV7SKA15

Coronary lesions in diabetics (DM) are associated with a high recurrence following percutaneous coronary intervention (PCI), even after drug-eluting stent (DES) deployment. Encouraging clinical data of the drug-eluting balloon catheter (DEB) SeQuent Please warrant its investigation in these patients.

Matched MeSH terms: Angioplasty, Balloon, Coronary/adverse effects; Angioplasty, Balloon, Coronary/instrumentation*; Angioplasty, Balloon, Coronary/mortality

Displaying publications 1 - 20 of 36 in total